Skip to main content

Articles

Page 16 of 39

  1. Immunotherapy has become an emerging strategy for the treatment of cancer. Immunotherapeutic drugs have been increasing for clinical treatment. Despite significant advances in immunotherapy, the clinical appli...

    Authors: Zhongwei Zhao, Liyun Zheng, Weiqian Chen, Wei Weng, Jingjing Song and Jiansong Ji
    Citation: Journal of Hematology & Oncology 2019 12:126
  2. Immunotherapy is a currently popular treatment strategy for cancer patients. Although recent developments in cancer immunotherapy have had significant clinical impact, only a subset of patients exhibits clinic...

    Authors: Li Yang, Aitian Li, Qingyang Lei and Yi Zhang
    Citation: Journal of Hematology & Oncology 2019 12:125
  3. Human pancreatic ductal adenocarcinoma (PDAC) responds poorly to immune checkpoint inhibitor (ICPi). While the mechanism is not completely clear, it has been recognized that tumor microenvironment (TME) plays ...

    Authors: Yu Pan, Fengchun Lu, Qinglin Fei, Xingxing Yu, Ping Xiong, Xunbin Yu, Yuan Dang, Zelin Hou, Wenji Lin, Xianchao Lin, Zheyang Zhang, Minggui Pan and Heguang Huang
    Citation: Journal of Hematology & Oncology 2019 12:124
  4. Mitosis is the process whereby an eukaryotic cell divides into two identical copies. Different multiprotein complexes are involved in the fine regulation of cell division, including the mitotic promoting facto...

    Authors: Andrea Ghelli Luserna di Rorà, Giovanni Martinelli and Giorgia Simonetti
    Citation: Journal of Hematology & Oncology 2019 12:123
  5. In the original article [1], the terms ‘osISET’ and ‘ISET’ within the ‘CTC capture’ sub-section of the Materials and Methods section have both been replaced with ‘CTCBIOPSY®’.

    Authors: Xiaobin Lin, Shuyi Wang, Min Sun, Chunxiao Zhang, Chen Wei, Chaogang Yang, Rongzhang Dou, Qing Liu and Bin Xiong
    Citation: Journal of Hematology & Oncology 2019 12:122

    The original article was published in Journal of Hematology & Oncology 2019 12:20

  6. N6-methyladenosine (m6A) methylation, one of the most common RNA modifications, has been reported to execute important functions that affect normal life activities and diseases. Most studies have suggested tha...

    Authors: Shuai Ma, Chen Chen, Xiang Ji, Jinbo Liu, Quanbo Zhou, Guixian Wang, Weitang Yuan, Quancheng Kan and Zhenqiang Sun
    Citation: Journal of Hematology & Oncology 2019 12:121
  7. The Editor-in-Chief would like to alert readers that the ownership of some of the data presented in this article [1]

    Authors: Benjamin Fourneaux, Aurélien Bourdon, Bérengère Dadone, Carlo Lucchesi, Scott R. Daigle, Elodie Richard, Audrey Laroche-Clary, François Le Loarer and Antoine Italiano
    Citation: Journal of Hematology & Oncology 2019 12:116

    The original article was published in Journal of Hematology & Oncology 2019 12:11

  8. Multiple myeloma (MM) is the second most common hematologic malignancy and remains incurable despite the advent of numerous new drugs such as proteasome inhibitors (PIs), immunomodulatory agents (IMiDs), and m...

    Authors: Chao Wu, Lina Zhang, Qierra R. Brockman, Fenghuang Zhan and Lijuan Chen
    Citation: Journal of Hematology & Oncology 2019 12:120
  9. Double-hit lymphoma (DHL) is among the most aggressive and chemoresistant lymphoma subtypes. DHLs carry genomic abnormalities in MYC, BCL2, and/or BCL6 oncogenes. Due to the simultaneous overexpression of thes...

    Authors: Yuanhui Liu, Nancy G. Azizian, Yaling Dou, Lan V. Pham and Yulin Li
    Citation: Journal of Hematology & Oncology 2019 12:119
  10. The original article [1] contains an error in authorship whereby author, Robert Weinkove’s name is mistakenly inverted. The configuration noted in this Correction article should be considered instead along wit...

    Authors: Jianyu Weng, Peilong Lai, Le Qin, Yunxin Lai, Zhiwu Jiang, Chenwei Luo, Xin Huang, Suijing Wu, Dan Shao, Chengxin Deng, Lisi Huang, Zesheng Lu, Maohua Zhou, Lingji Zeng, Dongmei Chen, Yulian Wang…
    Citation: Journal of Hematology & Oncology 2019 12:117

    The original article was published in Journal of Hematology & Oncology 2018 11:25

  11. Clonal evolution of chronic lymphocytic leukemia (CLL) often follows chemotherapy and is associated with adverse outcome, but also occurs in untreated patients, in which case its predictive role is debated. We...

    Authors: Alice Ramassone, Andrea D’Argenio, Angelo Veronese, Alessio Basti, Shimaa Hassan AbdelAziz Soliman, Stefano Volinia, Cristian Bassi, Sara Pagotto, Manuela Ferracin, Laura Lupini, Elena Saccenti, Veronica Balatti, Felice Pepe, Laura Z. Rassenti, Idanna Innocenti, Francesco Autore…
    Citation: Journal of Hematology & Oncology 2019 12:114
  12. Increased liver stiffness exerts a detrimental role in driving hepatocellular carcinoma (HCC) malignancy and progression, and indicates a high risk of unfavorable outcomes. However, it remains largely unknown ...

    Authors: Yinying Dong, Qiongdan Zheng, Zhiming Wang, Xiahui Lin, Yang You, Sifan Wu, Yaohui Wang, Chao Hu, Xiaoying Xie, Jie Chen, Dongmei Gao, Yan Zhao, Weizhong Wu, Yinkun Liu, Zhenggang Ren, Rongxin Chen…
    Citation: Journal of Hematology & Oncology 2019 12:112
  13. Breast cancer (BC) is a complex disease with primary or acquired incurability characteristics in a significant part of patients. Immunotherapeutical agents represent an emerging option for breast cancer treatm...

    Authors: E. Krasniqi, G. Barchiesi, L. Pizzuti, M. Mazzotta, A. Venuti, M. Maugeri-Saccà, G. Sanguineti, G. Massimiani, D. Sergi, S. Carpano, P. Marchetti, S. Tomao, T. Gamucci, R. De Maria, F. Tomao, C. Natoli…
    Citation: Journal of Hematology & Oncology 2019 12:111
  14. Liver cancer, mostly hepatocellular carcinoma (HCC), is the second leading cause of cancer mortality globally. Most patients need at least one systemic therapy at different phases of their treatment for HCC. S...

    Authors: Xiao-Dong Zhu and Hui-Chuan Sun
    Citation: Journal of Hematology & Oncology 2019 12:110
  15. The original article [1] contained an error in Fig. 7c whereby the same flow image was accidentally misused for the second and fourth group.

    Authors: Lufeng Zheng, Qianqian Guo, Chenxi Xiang, Shijia Liu, Yuzhang Jiang, Lanlan Gao, Haiwei Ni, Ting Wang, Qiong Zhao, Hai Liu, Yingying Xing, Yaohui Wang, Xiaoman Li and Tao Xi
    Citation: Journal of Hematology & Oncology 2019 12:109

    The original article was published in Journal of Hematology & Oncology 2019 12:23

  16. Assessment of measurable residual disease (MRD) is rapidly transforming the therapeutic and prognostic landscape of a wide range of hematological malignancies. Its prognostic value in acute lymphoblastic leuke...

    Authors: Jiří Pavlů, Myriam Labopin, Riitta Niittyvuopio, Gerard Socié, Ibrahim Yakoub-Agha, Depei Wu, Peter Remenyi, Jakob Passweg, Dietrich W. Beelen, Mahmoud Aljurf, Nicolaus Kröger, Hélène Labussière-Wallet, Zinaida Perić, Sebastian Giebel, Arnon Nagler and Mohamad Mohty
    Citation: Journal of Hematology & Oncology 2019 12:108
  17. Hodgkin lymphoma (HL) is an uncommon B cell lymphoma. We assessed the global, regional, and national burden of HL from 1990 to 2017, by gender, age, and social-demographic index (SDI).

    Authors: Linghui Zhou, Yujiao Deng, Na Li, Yi Zheng, Tian Tian, Zhen Zhai, Si Yang, Qian Hao, Ying Wu, Dingli Song, Dai Zhang, Jun Lyu and Zhijun Dai
    Citation: Journal of Hematology & Oncology 2019 12:107
  18. Cancer/testis antigens (CTAs) are a special type of tumor antigen and are believed to act as potential targets for cancer immunotherapy.

    Authors: Yuan Mao, Weifei Fan, Hao Hu, Louqian Zhang, Jerod Michel, Yaqin Wu, Jun Wang, Lizhou Jia, Xiaojun Tang, Li Xu, Yan Chen, Jin Zhu, Zhenqing Feng, Lin Xu, Rong Yin and Qi Tang
    Citation: Journal of Hematology & Oncology 2019 12:106
  19. Additional sex combs-like 1 (ASXL1) mutations have been described in all forms of myeloid neoplasms including chronic myelomonocytic leukemia (CMML) and associated with inferior outcomes, yet the molecular pathog...

    Authors: Rabindranath Bera, Ming-Chun Chiu, Ying-Jung Huang, Tung-Huei Lin, Ming-Chung Kuo and Lee-Yung Shih
    Citation: Journal of Hematology & Oncology 2019 12:104
  20. Circular RNAs (circRNAs) represent a type of endogenous noncoding RNAs that are generated by back-splicing events and favor repetitive sequences. Recent studies have reported that cancer-associated chromosomal...

    Authors: Wei Huang, Ke Fang, Tian-Qi Chen, Zhan-Cheng Zeng, Yu-Meng Sun, Cai Han, Lin-Yu Sun, Zhen-Hua Chen, Qian-Qian Yang, Qi Pan, Xue-Qun Luo, Wen-Tao Wang and Yue-Qin Chen
    Citation: Journal of Hematology & Oncology 2019 12:103
  21. Early diagnosis of CNS lymphoma (CNSL) is essential for successful therapy of this rapidly progressing brain tumor. However, in patients presenting with focal brain lesions, fast and reliable diagnosis of PCNS...

    Authors: Matthias Mulazzani, Marion Huber, Sabine Borchard, Sigrid Langer, Barbara Angele, Elisabeth Schuh, Edgar Meinl, Martin Dreyling, Tobias Birnbaum, Andreas Straube, Uwe Koedel and Louisa von Baumgarten
    Citation: Journal of Hematology & Oncology 2019 12:102
  22. Hepatocellular carcinoma (HCC) is a lethal disease, and recurrence and metastasis are the major causes of death in HCC patients. Cancer-associated fibroblasts (CAFs), a major stromal cell type in the HCC micro...

    Authors: Zeli Yin, Chengyong Dong, Keqiu Jiang, Zhe Xu, Rui Li, Kun Guo, Shujuan Shao and Liming Wang
    Citation: Journal of Hematology & Oncology 2019 12:101
  23. Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults, with an incidence that increases with age, and a generally poor prognosis. The disease is clinically and genetically heterogene...

    Authors: Catherine Lai, Kimberley Doucette and Kelly Norsworthy
    Citation: Journal of Hematology & Oncology 2019 12:100
  24. Cancer immunotherapy has been regarded as the most significant scientific breakthrough of 2013, and antibody therapy is at the core of this breakthrough. Despite significant success achieved in recent years, i...

    Authors: Qinghua He, Zhaoyu Liu, Zhihua Liu, Yuxiong Lai, Xinke Zhou and Jinsheng Weng
    Citation: Journal of Hematology & Oncology 2019 12:99
  25. The immunogenicity of a cancer cell is derived from accumulated somatic mutations. However, on the contrary to increased immunogenicity, anti-cancer immune response tends to be feeble. This impaired anti-cance...

    Authors: Anping Li, Ming Yi, Shuang Qin, Qian Chu, Suxia Luo and Kongming Wu
    Citation: Journal of Hematology & Oncology 2019 12:98
  26. Chemoresistance is one of the main causes of poor prognosis in pancreatic cancer patients. Understanding the mechanisms implicated in chemoresistance of pancreatic cancer is critical to improving patient outco...

    Authors: Guangbing Xiong, Chang Liu, Gang Yang, Mengyu Feng, Jianwei Xu, Fangyu Zhao, Lei You, Li Zhou, Lianfang Zheng, Ya Hu, Xiaowo Wang, Taiping Zhang and Yupei Zhao
    Citation: Journal of Hematology & Oncology 2019 12:97
  27. Cancer has become the second most serious disease threatening human health, followed by cardiovascular diseases. This study aimed to quantitatively estimate the mortality, morbidity, and analyze the trends of ...

    Authors: Longfei Lin, Lei Yan, Yuling Liu, Fang Yuan, Hui Li and Jian Ni
    Citation: Journal of Hematology & Oncology 2019 12:96
  28. Adipocytes are one of the primary stromal cells in many tissues, and they are considered to play an active role in the tumor microenvironment. Cancer-associated adipocytes (CAAs) are not only found adjacent to...

    Authors: Qi Wu, Bei Li, Zhiyu Li, Juanjuan Li, Si Sun and Shengrong Sun
    Citation: Journal of Hematology & Oncology 2019 12:95
  29. Antibody-drug conjugates (ADC) represent a distinct family of chemoimmunotherapy agents. ADCs are composed of monoclonal antibodies conjugated to cytotoxic payloads via specialized chemical linkers. ADCs there...

    Authors: Bo Yu and Delong Liu
    Citation: Journal of Hematology & Oncology 2019 12:94

    The Correction to this article has been published in Journal of Hematology & Oncology 2020 13:65

  30. Tumor neoantigen is the truly foreign protein and entirely absent from normal human organs/tissues. It could be specifically recognized by neoantigen-specific T cell receptors (TCRs) in the context of major hi...

    Authors: Tao Jiang, Tao Shi, Henghui Zhang, Jie Hu, Yuanlin Song, Jia Wei, Shengxiang Ren and Caicun Zhou
    Citation: Journal of Hematology & Oncology 2019 12:93
  31. Since the discovery of immune checkpoint proteins, there has been a special interest in developing antibodies that block programmed cell death 1 receptor (PD-1) and programmed cell death receptor ligand 1 (PD-...

    Authors: Akintunde Akinleye and Zoaib Rasool
    Citation: Journal of Hematology & Oncology 2019 12:92
  32. Long non-coding RNAs (lncRNAs) have been associated with non-small cell lung cancer (NSCLC), but the underlying molecular mechanisms of their specific roles in mediating aerobic glycolysis have been poorly exp...

    Authors: Qian Hua, Mingming Jin, Baoming Mi, Fei Xu, Tian Li, Li Zhao, Jianjun Liu and Gang Huang
    Citation: Journal of Hematology & Oncology 2019 12:91

    The Correction to this article has been published in Journal of Hematology & Oncology 2023 16:12

  33. Altered energy metabolism is a hallmark of tumors aiming at supplying necessary nutrients for tumorigenesis and development. These redirected metabolic pathways associated with carbohydrate, lipid and amino ac...

    Authors: Tao Yu, Yanfen Wang, Yu Fan, Na Fang, Tongshan Wang, Tongpeng Xu and Yongqian Shu
    Citation: Journal of Hematology & Oncology 2019 12:90
  34. The treatment of genitourinary malignancies has dramatically evolved over recent years. Renal cell carcinoma, urothelial carcinoma of the bladder, and prostate adenocarcinoma are the most commonly encountered ...

    Authors: Kevin Zarrabi, Azzam Paroya and Shenhong Wu
    Citation: Journal of Hematology & Oncology 2019 12:89
  35. Low-dose post-transplant cyclophosphamide (PTCy) in conjunction with anti-thymocyte globulin (ATG) appears as a potentially effective graft-versus-host disease (GVHD) prevention strategy in haploidentical hema...

    Authors: Yu Wang, De-Pei Wu, Qi-Fa Liu, Lan-Ping Xu, Kai-Yan Liu, Xiao-Hui Zhang, Wen-Jing Yu, Yang Xu, Fen Huang and Xiao-Jun Huang
    Citation: Journal of Hematology & Oncology 2019 12:88
  36. Haploidentical transplantation has been proposed as an effective treatment for severe aplastic anemia (SAA). The majority of patients have more than one HLA-haploidentical donor. Herein, we compared the outcom...

    Authors: Lan-Ping Xu, Shun-Qing Wang, Yan-Ru Ma, Su-Jun Gao, Yi-Fei Cheng, Yuan-Yuan Zhang, Wen-Jian Mo, Xiao-Dong Mo, Yu-Ping Zhang, Chen-Hua Yan, Yu-Hong Chen, Ming Zhou, Yu Wang, Xiao-Hui Zhang, Kai-Yan Liu and Xiao-Jun Huang
    Citation: Journal of Hematology & Oncology 2019 12:87
  37. Among all the stromal cells that present in the tumor microenvironment, cancer-associated fibroblasts (CAFs) are one of the most abundant and critical components of the tumor mesenchyme, which not only provide...

    Authors: Tongyan Liu, Chencheng Han, Siwei Wang, Panqi Fang, Zhifei Ma, Lin Xu and Rong Yin
    Citation: Journal of Hematology & Oncology 2019 12:86
  38. We tested whether a single nucleotide polymorphism (SNP) that affects splicing of CD33 predicted response to treatment in adults with acute myeloid leukemia (AML) who received the novel CD33 antibody-drug conj...

    Authors: Michele Stanchina, Alessandro Pastore, Sean Devlin, Christopher Famulare, Eytan Stein and Justin Taylor
    Citation: Journal of Hematology & Oncology 2019 12:85
  39. Plenty of immune cells infiltrate into the tumor microenvironment (TME) during tumor progression, in which myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population of immature myeloid cell...

    Authors: Xinyu Tian, Han Shen, Zhiyang Li, Tingting Wang and Shengjun Wang
    Citation: Journal of Hematology & Oncology 2019 12:84
  40. The original article [1] contains an error in Fig. 2 whereby Fig. 2D has mistakenly been omitted. Fig. 2 can be viewed in its entirety – including Fig. 2D – in this Correction article.

    Authors: Wenwu Xiao, Weijie Ma, Sixi Wei, Qianping Li, Ruiwu Liu, Randy P. Carney, Kevin Yang, Joyce Lee, Alan Nyugen, Ken Y. Yoneda, Kit S. Lam and Tianhong Li
    Citation: Journal of Hematology & Oncology 2019 12:83

    The original article was published in Journal of Hematology & Oncology 2019 12:56

  41. Lymphomas are a heterogeneous group of lymphoproliferative disorders, with unique clinical and biological characteristics that exhibit variable response to therapy. Advances in chemo-immunotherapy have improve...

    Authors: Sabarish Ayyappan and Kami Maddocks
    Citation: Journal of Hematology & Oncology 2019 12:82

    The Correction to this article has been published in Journal of Hematology & Oncology 2021 14:28

  42. Tamoxifen resistance remains a clinical challenge for hormone receptor-positive breast cancer. Recently, dysregulations in autophagy have been suggested as a potential mechanism for tamoxifen resistance. Altho...

    Authors: Ji Wang, Shuduo Xie, Jingjing Yang, Hanchu Xiong, Yunlu Jia, Yulu Zhou, Yongxia Chen, Xiaogang Ying, Cong Chen, Chenyang Ye, Linbo Wang and Jichun Zhou
    Citation: Journal of Hematology & Oncology 2019 12:81
  43. Nucleophosmin-anaplastic lymphoma kinase-expressing (NPM-ALK+) T cell lymphoma is an aggressive neoplasm. NPM-ALK, an oncogenic tyrosine kinase, plays a critical role in this lymphoma. Recently, selective ALK inh...

    Authors: Bhawana George, Suraj Konnath George, Wenyu Shi, Abedul Haque, Ping Shi, Ghazaleh Eskandari, Magnus Axelson, Olle Larsson, Ahmed O. Kaseb and Hesham M. Amin
    Citation: Journal of Hematology & Oncology 2019 12:80

    The Correction to this article has been published in Journal of Hematology & Oncology 2023 16:61

  44. The biological function of protein arginine methyltransferase 3 (PRMT3) is not well known because very few physiological substrates of this methyltransferase have been identified to date.

    Authors: Ming-Chuan Hsu, Ya-Li Tsai, Chia-Hsien Lin, Mei-Ren Pan, Yan-Shen Shan, Tsung-Yen Cheng, Skye Hung-Chun Cheng, Li-Tzong Chen and Wen-Chun Hung
    Citation: Journal of Hematology & Oncology 2019 12:79
  45. While promising, immunotherapy has yet to be fully unlocked for the preponderance of cancers where conventional chemoradiation reigns. This remains particularly evident in pediatric sarcomas where standard of ...

    Authors: Kyle A. Dyson, Brian D. Stover, Adam Grippin, Hector R. Mendez-Gomez, Joanne Lagmay, Duane A. Mitchell and Elias J. Sayour
    Citation: Journal of Hematology & Oncology 2019 12:78

Annual Journal Metrics

  • 2022 Citation Impact
    28.5 - 2-year Impact Factor
    23.1 - 5-year Impact Factor
    4.045 - SNIP (Source Normalized Impact per Paper)
    6.046 - SJR (SCImago Journal Rank)

    2023 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    59 days submission to accept (Median)

    2023 Usage 
    3,173,795 downloads
    2,671 Altmetric mentions

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here